NDAINJECTIONINJECTABLEPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTIN F2 ALPHA (dinoprost tromethamine) is a prostaglandin F2-alpha analog administered by injection. It is used to induce abortion, control postpartum hemorrhage, and manage other obstetric/gynecological conditions. The drug works by stimulating uterine contractions through prostaglandin receptor activation.
PRE_LAUNCH
Pre-launch stage indicates heavy investment in launch readiness; commercial teams will focus on market planning, payer strategy, and field infrastructure build-out.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PROSTIN F2 ALPHA during its pre-launch phase offers career visibility and leadership opportunities in product commercialization strategy, regulatory navigation, and obstetric market positioning. This stage is ideal for professionals seeking hands-on experience building market infrastructure and launch execution from the ground up.
Launch ManagerBrand Manager
Worked on PROSTIN F2 ALPHA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.